-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yimaitong compiled and sorted, please do not reprint
without permission.
Introduction: Evidence suggests that metabolic disorders (e.
g.
, hormonal disturbances, physical fatigue, etc.
) occur after papillary thyroid carcinoma (PTC) resection, even after which the patient is treated with thyrotropin (TSH) suppression
.
However, the specific metabolomic characteristics of patients after surgery are not clear
.
Recently, a study published at the 2022 American Thyroid Association Annual Meeting (2022ATA) confirmed that patients after thyroidectomy still have significant metabolic disorders after thyrotropin suppressive therapy, and the study observed an increase
in the level of 66 lipid-related metabolites.
Exploration: Metabolomic features after thyroidectomy
To understand the metabolomic profile after thyroidectomy, 50 patients with PTC without metabolic disease were included in the study, with the same
number of patients who underwent either full (T) or unilateral (L) thyroidectomy.
Patient clinical features and fasting serum samples
were collected before surgery (T0) and 1 month after surgery (T1).
Serum metabolome characterization
was detected by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).
Postoperative lipid metabolite indicators increased
The results were compared, before and after surgery, and the characteristics
of patient metabolism between different procedures.
Compared with the T0 group, the metabolomics in the T1 group was significantly
different.
Levels of 66 lipid-associated metabolites increased and levels of one nucleotide metabolite decreased (OPLS-DAVIP>2.
0), while TSH levels did not change
significantly.
Among these metabolites, lipids such as long- and short-chain fatty acids account for the vast majority, which also represents a significant change in
β-oxidation and omega-oxidation levels.
Comparison of results between different surgical modalities showed that the main difference between the T and L groups was the secondary bile acid metabolism and the different
levels of benzoic acid metabolism.
Summary of this article
The results of the study confirmed that patients with PTC who recovered with TSH suppression had metabolic disorders, indicating that levothyroxine does not completely compensate for impaired thyroid function
.
Therefore, clinical attention should be paid to postoperative metabolic disorders and long-term quality of life
in PTC patients.
REFERENCE: LONG‐TERM MORTALITY AND CARDIOMETABOLIC EFFECTS OF TREATMENT FOR HYPERTHYROIDISM: EGRET STUDY.
THYROID
Volume 32, Supplement 1,2022.
https://doi.
org/10.
1089/thy.
2022.
29140.
lb.
abstracts